Ownership and insider activity for Serina Therapeutics, Inc. (SER): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy.
Price
| Price | $2.16 |
| Market Cap | $32M |
| Exchange | AMEX |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-07-22 | Simon Farrell | A-Award | 30,500 | $66K |
| 2026-07-22 | Simon Farrell | |||
| 2026-07-07 | Brannan Stephen K. | P-Purchase | 1,000 | $2K |
| 2026-06-17 | Venkatesan Jay | C-Conversion | 224,152 | $504K |
| 2026-06-17 | Venkatesan Jay | A-Award | 15,250 | $30K |
| 2026-05-22 | Venkatesan Jay | P-Purchase | 589 | $1K |
| 2026-06-17 | Venkatesan Jay | C-Conversion | 96,525 | $500K |
| 2026-06-17 | Bailey Gregory | C-Conversion | 6,666,667 | $15.0M |
| 2026-06-17 | Bailey Gregory | A-Award | 3,333,333 | $16.7M |
| 2026-06-17 | Bailey Gregory | C-Conversion | 1,770,805 | $4.0M |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $259000 | $7.4M | $6.7M | $2.4M | $527000 | $584000 | $645000 | $7.6M | $3.7M | $3.1M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $308000 | $107000 | $131000 | $363000 | $326000 | $25000 | $4000 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $688000 | $7.6M | $7.9M | $4.1M | $2.3M | $2.2M | $2.5M | $7.6M | $5.7M | $6.1M |
| Property, Plant & Equipment | $195000 | $129000 | $90000 | $1.1M | 0 | 0 | 0 | $1.3M | $1.0M | $842000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | $2.2M | $1.6M | 0 | $738000 | 0 | 0 | 0 |
| Total Assets | $3.2M | $9.6M | $10.7M | $7.4M | $3.9M | $3.2M | $3.2M | $9.0M | $6.7M | $7.0M |
| Accounts Payable | $261000 | $75000 | $150000 | $420000 | $761000 | $193000 | $568000 | $580000 | $744000 | $1.9M |
| Short-term Debt | 0 | 0 | 0 | $428000 | $2.4M | $7.1M | $7.6M | 0 | 0 | 0 |
| Total Current Liabilities | $25.6M | $1.3M | $2.4M | $3.3M | $5.4M | $9.0M | $10.1M | $1.4M | $2.4M | $3.6M |
| Long-term Debt | 0 | 0 | 0 | $1.5M | $3.9M | $6.1M | $10.5M | $3.0M | 0 | $196000 |
| Total Liabilities | $25.6M | $1.3M | $2.4M | $4.8M | $9.3M | $15.0M | $20.6M | $41.3M | $6.2M | $7.0M |
| Retained Earnings | -$60.0M | -$66.6M | -$74.1M | -$86.2M | -$97.1M | -$105.7M | -$116.2M | -$33.2M | -$44.3M | -$63.5M |
| Total Equity | -$23.4M | $7.3M | $7.4M | $2.2M | -$5.1M | -$11.8M | -$17.2M | -$32.3M | $641000 | -$37000 |
| Total Debt | 0 | 0 | 0 | $2.0M | $6.3M | $13.2M | $18.1M | $3.4M | $268000 | $196000 |
| Net Debt | -$259000 | -$7.4M | -$6.7M | -$396000 | $5.8M | $12.6M | $17.5M | -$4.2M | -$3.4M | -$2.9M |
| Working Capital | -$24.9M | $6.3M | $5.4M | $757000 | -$3.1M | -$6.7M | -$7.6M | $6.2M | $3.3M | $2.5M |
Financial Health
| Debt / Equity | 0.17 |
| Current Ratio | 6.65 |
Profitability
| Return on Equity | -222.42% |
| Return on Invested Capital | -116.37% |
| Return on Assets | -82.03% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ALGS · BRNS · CVM · GNTA · GRCE · INMB · JUNS
Explore sector: Healthcare · Biotechnology
More sections of SER: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks